Effectiveness of the exercise training therapy for the dialysis dependent end-stage renal disease patients and the myokines, which is skeletal muscle derived physiologically active substance
Not Applicable
- Conditions
- Chronic kidney disease
- Registration Number
- JPRN-UMIN000041181
- Lead Sponsor
- Kaikoukai Healthcare Corporation
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- All
- Target Recruitment
- 40
Inclusion Criteria
Not provided
Exclusion Criteria
1) Under 20 years old or 90 years or older 2) Need a walking aid and assistance at a walk 3) Needed hospitalizing having acute disease within the past three months 4) Serious heart failure 5) Arrhythmia and the blood pressure abnormality that it is poor in management 6) Severe locomotorium disease including the articular rheumatism 7) Malignant tumor 8) AIDS
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method The change of myokines Interleukin-6 (IL-6), Fibroblast growth factor 21 (FGF-21), Follistatin-like1 (FSTL1), Myonectin and adipo-cytokines (adiponectin, omentin) between pre, 6 months, and one year after exercise training therapy
- Secondary Outcome Measures
Name Time Method 1.The change of myocardial flow reserve measured by ammonia PET between pre and one year after exercise training therapy 2.The change of Blood biochemistry findings, 12-lead electrocardiogram findings, echocardiography findings, body function evaluation (physical active mass, isometric knee extension muscular strength, muscle mass, exercise tolerance (CPX), Short Physical Performance Battery(SPPB) between pre, 6 month, and one years after exercise training therapy 3.Prognostic parameter after exercise training therapy